Hypoxia and Tumor Microenvironment

Implications for Cancer Therapy
Erscheinungsjahr 2025
ISBN: 978-981-961015-0
Verlag: Springer Nature Singapore

Buch, Englisch, 236 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 591 g

This book provides a comprehensive overview of the hypoxic tumor microenvironment and its impact on various aspects of cancer biology, including DNA damage response, genome instability, tumor immunity, non-coding RNA regulation, metabolic regulation of CAR-T cell function, and angiogenesis. It explores the regulation and therapeutic potential of hypoxia-inducible factors, as well as strategies to improve cancer immunotherapy by targeting the hypoxic tumor microenvironment.

This book is a valuable resource for students, researchers, and Medical science professionals interested in understanding the complex interplay between hypoxia and cancer biology.

Zielgruppe

Research

Autoren/Hrsg.

Kanwar, Jagat Rakesh

Mukherjee, Sukhes

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

.- Chapter 1: Tumor Hypoxia  An Introduction
.- Chapter 2: Hypoxia and tumor immunity
.- Chapter 3: Incipient Role of Non coding RNAs in  different types of cancer hypoxia
.- Chapter 4: Hypoxia induced DNA damage response and genomic instability dictate cancer treatment response
.- Chapter 5: Metabolic regulation of CAR T cell function by hypoxic tumor
.- Chapter 6: Emerging roles of non coding RNAs in tumor hypoxia
.- Chapter 7: Regulation of Angiogenesis by Cancer Hypoxia and Role of Hypoxia Inducible Factors with Therapeutic Paradigm
.- Chapter 8: Hypoxia and Regulation of Cancer Cell Stemness
.- Chapter 9: Hypoxia-Inducible Factors: Regulation and Therapeutic Potential in Cancer: Artificial Intelligence in Precision Medicine
.- Chapter 10: Strategic application of bio reductive metalloprodrugs for cancer cell-selective anticancer therapy
.- Chapter 11: Hypoxia Inducible Factors  Regulation and Therapeutic Potential.

Über Autor(innen)

Dr Sukhes Mukherjee is working as an Additional Professor in the Biochemistry Department of All India Institute of Medical Sciences (AIIMS), Bhopal, MP, India. He is involved in teaching and research for the last 18 years with a very active academic and research career.   Dr. Mukherjee has published more than 80 papers in peer-reviewed journals and presented his work at several national and international conferences. He got the best paper award from the “Association of Clinical Biochemists of India” in 2008. He got the international travel fellowship to attend the Neurochemistry conference at Busan, South Korea, in August 2009 and another AACC fellowship in 2011. Dr. Mukherjee has been awarded by the International Society for Neurochemistry in 2008 and is a member of the National Academy of Medical Sciences, India (MAMS).  He is also the executive committee member of various national and international scientific organizations. Dr. Mukherjee integratesnew technologies into everyday clinical practice and finds new areas in biomedical research advancement, particularly in Cancer Biology.

Dr Jagat R Kanwar is a Professor and Head of the Department of Biochemistry at All India Institute of Medical Sciences (AIIMS), Bhopal, MP, India. He is the highly cited (globally top 2% highly cited ranked) researcher in 3 disciplines of science (field of oncology, medical chemistry and nanotechnology). Dr. Kanwar earned his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in 1993. In 2002 he joined as a Senior Scientist/Senior Research Fellow at The University of Auckland. Professor Kanwar is the group leader and laboratory head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research in the School of Medicine, Faculty of Health at Deakin University. Professor Kanwar is currently working on nanotechnology/nanomedicine-based protein/peptide, aptamers and his research approach employs monotherapy (gene therapy, immunotherapy) and combinational therapy with commercially available chemotherapeutic agents including LNA-aptamers (RNA/DNA), peptides and other biomolecules such as siRNA, miRNA, aptamers, proteins, siRNA, miRNA and their chimera in cancer and chronic inflammation.